Edgemont Capital Partners

Edgemont Capital Partners advises Questcor Pharmaceuticals on the sale of its Nascobal® product line to QOL Medical

Union City, CA, October 17, 2005

Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders, today announced the completion of a transaction to divest its non-core pharmaceutical products, in accordance with its new central nervous system (CNS) strategy. Questcor completed the sale of its Nascobal(R), Ethamolin(R) and Glofil(R)-125 products to QOL Medical LLC for $28.3 million, plus the assumption by QOL of the obligation to pay Nastech Pharmaceutical Company Inc. (NasdaqNM: NSTK) $2 million on the issuance by the US Patent and Trademark Office of a patent on Nascobal Nasal Spray.

Read the complete press release

Edgemont Capital Partners advises MedSN on merger with Indegene

Los Angeles, CA, and Bangalore, India / September 13, 2005

MedSN, Inc., a leading medical education, sales training, and marketing services provider based in the United States, today announced that it has merged with the Indegene group of companies, the preeminent medical education, training, and marketing services provider in India and Asia.

Read the complete press release

Edgemont Capital Partners advises Hollister-Stier Laboratories on the divestiture of its Twinject™ allergy product line to Verus Pharmaceuticals

San Diego, CA, July 6, 2005

Verus Pharmaceuticals, Inc., a pediatric-oriented company dedicated to identifying, developing and delivering solutions to address the unmet medical needs of children and those who care for them, today announced it has acquired exclusive, worldwide rights to Twinject™ from Hollister-Stier Laboratories LLC. Twinject, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was approved by the U.S. Food and Drug Administration (FDA) in 2003; two dosages are now approved for self-administration (0.3 mg and 0.15 mg). In addition to Twinject, Verus has acquired rights to other intellectual property and assets, including complementary and next generation device designs and on-going development programs.

Read the complete press release

Edgemont Capital Partners advises PharmAnalysis Group, Inc. on its acquisition by United BioSource Corp.

Bethesda, MD, August 9, 2004

MEDTAP® International, Inc. (a subsidiary of United BioSource Corp.) announced today that it has broadened its research and consultation services to include strategic reimbursement planning through the addition of PharmAnalysis Group, Inc., a provider of reimbursement planning for the pharmaceutical, biotechnology, medical device and diagnostics industries, as MEDTAP's new Center for Pricing and Reimbursement. With this addition, MEDTAP, a global research organization specializing in outcomes research, economic evaluation and policy research, adds strategic consulting in pricing and reimbursement to its array of existing services.

Read the complete press release

Edgemont Capital Partners advises POZEN on the licensing of MT 300 to Xcel Pharmaceuticals

Chapel Hill, NC & San Diego, CA, September 4, 2003

POZEN Inc. (NASDAQ: POZN) and Xcel Pharmaceuticals, Inc. (Xcel) announced today that they have signed an agreement for the commercialization of MT 300(TM) that may provide a new and effective injectable treatment for patients suffering from severe migraine headaches. MT 300 is being developed as an improved and highly purified formulation of dihydroergotamine mesylate (DHE) in a convenient pre-filled syringe that is suitable for at-home use. As previously announced, POZEN submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of MT 300 on December 17, 2002. The application is currently under review at the FDA.

Read the complete press release

Desitin Retains Edgemont Capital Partners as Exclusive Financial Advisor And Representative

Hamburg, & New York City, August 8, 2003

Desitin Arzneimittel GmbH and Edgemont Capital Partners today announced that Desitin has engaged Edgemont as its exclusive financial advisor and representative. Edgemont will work to secure a U.S. commercialization partner for the Company's novel, once- daily, sustained release oral formulation of oxcarbazepine. Oxcarbazepine is currently marketed in the U.S. exclusively by Novartis under the brand name Trileptal(tm) as a twice-a-day therapy for the treatment of epilepsy, and had U.S. sales of $212 million in 2002.

Read the complete press release

Edgemont Capital Partners advises Nastech Pharmaceutical Company on the sale of the Nascobal® product line

Bothell, WA, June 17, 2003

Nastech Pharmaceutical Company, Inc. (Nasdaq: NSTK), a leader in nasal drug delivery technology, announced today that Questcor Pharmaceuticals, Inc. (Amex: QSC) is acquiring Nastech's Nascobal® product, including the FDA- approved Nascobal® (Cyanocobalamin USP) nasal gel and the Nascobal® nasal spray, which is pending FDA approval. The transaction includes all Nascobal® intellectual property, marketing rights, inventory, trademarks, confidential know-how, contracts, and records.

Edgemont Capital Partners has acted as Nastech's investment banking advisor on this transaction.

Read the complete press release

Managing Director David Blume is interviewed by The Wall Street Transcript

New York NY, March 2003

Click here to read David's interview (Requires Acrobat Reader. Get it here.)

Edgemont Capital Partners advises CroMedica, Inc. on merger with PRA
International, Inc.

McLean, VA, June 17, 2002

PRA International Inc, a pharmaceutical research industry leader in contract clinical development services, today announced that it has agreed to a merger with CroMedica International, Inc, a worldwide clinical research organization (CRO) headquartered in Canada. The combined companies will operate under the PRA International name, forming one of the top five global clinical drug development organizations.